Breakthrough infections, hospital admissions, and mortality after major COVID-19 vaccination profiles: A prospective cohort study.

Wichaidit, Mingkwan, Nopsopon, Tanawin, Sunan, Krittiyaporn, Phutrakool, Phanupong, Ruchikachorn, Puripant, Wanvarie, Dittaya, Pratanwanich, Ploy Naruemon, Cheewaruangroj, Nontawit, Punyabukkana, Proadpran and Pongpirul, Krit ORCID: 0000-0003-3818-9761 (2023) Breakthrough infections, hospital admissions, and mortality after major COVID-19 vaccination profiles: A prospective cohort study. The Lancet regional health. Southeast Asia, 8. p. 100106.

Access the full-text of this item by clicking on the Open Access link.

Official URL: http://dx.doi.org/10.1016/j.lansea.2022.100106

Abstract

<h4>Background</h4>Several COVID-19 vaccination rollout strategies are implemented. Real-world data from the large-scale, government-mandated Central Vaccination Center (CVC), Thailand, could be used for comparing the breakthrough infection, across all available COVID-19 vaccination profiles.<h4>Methods</h4>This prospective cohort study combined the vaccine profiles from the CVC registry with three nationally validated outcome datasets to assess the breakthrough COVID-19 infection, hospitalization, and death among Thais individuals who received at least one dose of the COVID-19 vaccine. The outcomes were analyzed by comparing vaccine profiles to investigate the shot effect and homologous effect.<h4>Findings</h4>Of 2,407,315 Thais who had at least one dose of COVID-19 vaccine, 63,469 (2.75%) had breakthrough infection, 42,001 (1.79%) had been hospitalized, and 431 (0.02%) died. Per one vaccination shot added, there was an 18% risk reduction of breakthrough infection (adjusted hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.80-0.82), a 25% risk reduction of hospitalization (HR 0.75, 95% CI 0.73-0.76), and a 96% risk reduction of mortality (HR 0.04, 95% CI 0.03-0.06). The heterologous two-shot vaccine profiles had a higher protective effect against infection, hospitalization, and mortality compared to the homologous counterparts.<h4>Interpretation</h4>COVID-19 breakthrough infection, hospitalization, and death differ across vaccination profiles that had a different number of shots and types of vaccines.<h4>Funding</h4>This study did not involve any funding.

Item Type:	Article
Uncontrolled Keywords:	AZ, ChAdOx1 nCoV-19, Vaxzevria, Cambridge, AstraZeneca, UK, CO-Ward, Thai COVID-19 hospitalization dataset, CVC, central vaccination center, Co-Lab, Thai COVID-19 infection dataset, IN, inactivated vaccine, IgG, immunoglobulin G, MN, mRNA-1273, Moderna, NIAID, USA, MR, mRNA vaccine, PDPA, Personal Data Protection Act, PEC, primary eligibiligy criteria, PZ, BNT162b2, Comirnaty, BioNTech, Mainz, Germany, RT-PCR, reverse transcription-polymerase chain reaction, SP, Sinopharm, Beijing Institute of Biological Products, China, SV, CoronaVac, Sinovac Biotech, Beijing, China, VSDMC, Vaccine Safety and Data Monitoring Committee, VV, viral vector vaccine
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Infection, Veterinary and Ecological Sciences
Depositing User:	Symplectic Admin
Date Deposited:	06 Mar 2024 10:26
Last Modified:	06 Mar 2024 10:26
DOI:	10.1016/j.lansea.2022.100106
Open Access URL:	https://doi.org/10.1016/j.lansea.2022.100106
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3179160